TABLE III

Results of recent trials of treatments for prevention of stroke in atrial fibrillation.From Nolan and Bloomfield49

Relative risk
of warfarin
treatment
%
Annual event rate(%)
TrialNo of
patients
TretmentsFollow up
(years)
PlaceboWarfarin
Atrial fibrillation, aspirin, antikoagulation1007Placebo (upsilion) aspirin (upsilion) warfarin(dagger)4.8*1.4*71
Boston area anticoagulation trial for atrial fibrillation420Placebo (upsilion) warfarin2.22.90.486
Stroke prevention in atrial fibrillation1330Placebo (upsilion) aspirin (upsilion) warfarin1.37.42.367
Canadian atrial fibrillation anticoagulation study(double dagger)378Placebo (upsilion) warfarin1.33.72.143
Stroke prevention in non-rheumatic atrial fibrillation571Placebo (upsilion) warfarin1.84.30.979
  • *Overall event rate.

  • (dagger)Not known.

  • (double dagger)Terminated early.